bluebird bio Inc. [BLUE] moved up 21.14: Why It’s Important


bluebird bio Inc. [NASDAQ: BLUE] price surged by 21.14 percent to reach at $0.63. The company report on June 7, 2022 that bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


June 9 discussion will focus on eli-cel for the treatment of early active cerebral adrenoleukodystrophy in patients without a matched sibling donor and overall safety of lentiviral vector (LVV) gene therapy.

June 10 discussion will focus on beti-cel for the treatment of β-thalassemia in patients who require regular red blood cell transfusions.

A sum of 4922352 shares traded at recent session while its average daily volume was at 2.49M shares. bluebird bio Inc. shares reached a high of $3.6192 and dropped to a low of $2.93 until finishing in the latest session at $3.61.

The one-year BLUE stock forecast points to a potential upside of 50.75. The average equity rating for BLUE stock is currently 3.20, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on bluebird bio Inc. [BLUE]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BLUE shares is $7.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BLUE stock is a recommendation set at 3.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cowen have made an estimate for bluebird bio Inc. shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on April 06, 2022. The new note on the price target was released on March 07, 2022, representing the official price target for bluebird bio Inc. stock. Previously, the target price had yet another drop from $25 to $16, while Wells Fargo kept a Equal Weight rating on BLUE stock. On November 08, 2021, analysts decreased their price target for BLUE shares from 22 to 11.

The Average True Range (ATR) for bluebird bio Inc. is set at 0.35, with the Price to Sales ratio for BLUE stock in the period of the last 12 months amounting to 53.50. The Price to Book ratio for the last quarter was 1.01, with the Price to Cash per share for the same quarter was set at 3.04.

BLUE Stock Performance Analysis:

bluebird bio Inc. [BLUE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.81. With this latest performance, BLUE shares dropped by -3.22% in over the last four-week period, additionally sinking by -63.94% over the last 6 months – not to mention a drop of -83.00% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BLUE stock in for the last two-week period is set at 52.65, with the RSI for the last a single of trading hit 59.08, and the three-weeks RSI is set at 48.76 for bluebird bio Inc. [BLUE]. The present Moving Average for the last 50 days of trading for this stock 3.93, while it was recorded at 3.16 for the last single week of trading, and 10.19 for the last 200 days.

Insight into bluebird bio Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and bluebird bio Inc. [BLUE] shares currently have an operating margin of -15322.36 and a Gross Margin at -1000.66. bluebird bio Inc.’s Net Margin is presently recorded at -15364.23.

Return on Equity for this stock declined to -65.07, with Return on Assets sitting at -47.38.

bluebird bio Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.80.

bluebird bio Inc. [BLUE] Insider Position Details

There are presently around $187 million, or 89.70% of BLUE stock, in the hands of institutional investors. The top three institutional holders of BLUE stocks are: STATE STREET CORP with ownership of 13,151,891, which is approximately 72.658% of the company’s market cap and around 1.50% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 6,140,000 shares of the stock with an approximate value of $18.3 million in BLUE stocks shares; and VANGUARD GROUP INC, currently with $17.66 million in BLUE stock with ownership of nearly -18.055% of the company’s market capitalization.

Positions in bluebird bio Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 93 institutional holders increased their position in bluebird bio Inc. [NASDAQ:BLUE] by around 17,397,960 shares. Additionally, 78 investors decreased positions by around 12,935,046 shares, while 41 investors held positions by with 32,530,034 shares. The mentioned changes placed institutional holdings at 62,863,040 shares, according to the latest SEC report filing. BLUE stock had 32 new institutional investments in for a total of 3,965,085 shares, while 34 institutional investors sold positions of 9,908,824 shares during the same period.